Presented in partnership with Cancer Support Community
This workshop will raise awareness among patients and caregivers about diagnoses, treatment options, managing side effects, coping with the psychosocial impact of neuroendocrine and carcinoid tumors, and fostering constructive dialogue with their healthcare team.
Presenters will include Dr. Giuseppe Esposito, Chief of Nuclear Medicine and PET/CT and Professor of Radiology at the Medstar Georgetown University Hospital, and Dr. Jaydira del Rivero, endocrine oncologist in the Pediatric Oncology Branch (POB) at the National Cancer Institute Center for Cancer Research.
Enrollment space is limited and we expect this workshop to fill quickly, so register early to guarantee your place! To RSVP, please click the link at the top of this page, call 202.483.8600 or email programs@smithcenter.org.
About Giuseppe Esposito, MD, MBA
Giuseppe Esposito, MD, is board certified in nuclear medicine. He sees patients at two MedStar clinics the Reservoir Road clinic in Washington, DC, and the Olney, Maryland clinic. Dr. Esposito is the Chief of Nuclear Medicine and PET/CT and Professor of Radiology at the Medstar Georgetown University Hospital. His specialties include PET/CT and SPECT/CT imaging of tumors, cardiac diseases, epilepsy, dementias and Parkinson’s disease.
In his clinics, he also performs diagnostic imaging and treatment of thyroid cancer and hyperthyroidism, prostate bone metastases, radioembolization of metastatic liver cancers, and PRRT treatment of Neuroendocrine tumors. Dr. Esposito is very active in research and in conducting clinical trials. He is also involved in the professional Society of Nuclear Medicine and Molecular Imaging. He serves as a peer reviewer for multiple medical journals, including Frontiers in Oncology, Frontiers in Cancer Imaging and Diagnosis. Dr. Esposito enjoys talking with his patients and answering their questions. Many patients are not familiar with nuclear medicine, so he takes great care to explain the procedures to make patients feel comfortable educating them on the benefits and the potential side effects.
Dr. Esposito is a native of Italy and has lived in the U.S. since 1992. He travels to Italy frequently, with his wife and two daughters, to see the rest of his family in Naples.
About Jaydira Del Rivero, M.D.
Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internship at General Hospital Institute of Security and Social Services for Government Employees, also in Veracruz. Following a year of field service at the Center of Studies and Health Services at the University of Veracruz. Dr. Del Rivero completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center in Brooklyn. Dr. Del Rivero completed a fellowship in endocrinology at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma, rare tumors that form within and outside the adrenal glands and are linked to a range of inherited syndromes. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she focused on all endocrine tumors such as thyroid cancer, parathyroid tumors, advanced gastroenteropancreatic neuroendocrine tumors, adrenal tumors, pheochromocytoma/paraganglioma and other endocrine malignancies.
She subsequently completed a second fellowship in oncology at the National Cancer Institute with a research focus on endocrine malignancies such as medullary thyroid cancer. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and board eligible in Oncology.
She is developing the Rare Tumor Natural History study and Rare Tumor Clinic to: 1) serve as an umbrella protocol for patients with rare solid tumors of interest to the CCR and for patients who may be candidates for CCR early clinical trials and, 2) to provide the basis for the development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient-reported outcome measures.
She is also working on tumor immunology and the development of novel immunotherapy approaches for medullary thyroid cancer and targeted therapies for other endocrine malignancies such as advanced pheochromocytoma/paraganglioma.
.jpg)
